Firefly Neuroscience Reports 373% Year-Over-Year Increase in U18 ADHD Evoke™ Scans as Commercial Expansion Accelerates
The Manila Times
Firefly Neuroscience reported a 373% year-over-year increase in U18 ADHD Evoke™ scans, driven by growing clinical adoption and commercial expansion. The company is leveraging its nationwide network to cross-sell non-drug ADHD treatments, aiming to create an end-to-end diagnostic-to-treatment model. The surge in scans also enhances Firefly's AI foundation through its expanding proprietary dataset of over 200,000 brain scans.
All articles from 17 November 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.
Get this news by email
Daily or as a weekly roundup in your inbox. You confirm your address first; every email has an unsubscribe link. For another topic or language, use the subscribe page.